1. FDA. Guidance on statistical procedures for bioequivalence studies using a standard two-treatment crossover design. Informal communication by the Division of Bioequivalence, Office of Generic Drugs, Rockville, MD; 1992.
2. Commission of the European Communities. CPMP Working Party on Efficacy of Medicinal Products. Note for guidance: Investigation of bioavailability and bioequivalence; 1991.
3. Anderson S, Hauck WW. Considerations of individual bioequivalence. J Pharmacokin Biopharm. 1990; 18(3): 259–273.
4. Hauck WW, Anderson S. Individual vs. average bioequivalence: when is average not sufficient. Proceedings of Bio-International ’94. Munich; 1994.
5. Schall R. A unified view of individual, population and average bioequivalence. Proceedings of Bio-International ’94. Munich; 1994.